Compare AbbVie Inc (ABBV) vs Canadian National Railway Co. (CNI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Canadian National Railway Co. — how do they compare? AbbVie Inc trades at $253.47 (market cap $449.91B), while Canadian National Railway Co. trades at $122.73 (market cap $74.49B). The key difference: AbbVie Inc is far larger — about 6× Canadian National Railway Co.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CNI | |
|---|---|---|
Market Cap | $449.91B | $74.49B |
Sector | Health | Industrials |
52-Week High | $261.07 | $122.78 |
52-Week Low | $184.85 | $90.91 |
Enterprise Value | $513.38B | $89.95B |
Dividend Yield | 2.72% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
CNI trades at $122.78, up 1.0% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS in line with expectations at $1.31, following beats in prior quarters, and maintains strong profitability with a 27.23% net income margin. Recent news highlights operational records in propane and grain shipments, alongside a new rail agreement for BHP's Jansen Potash Mine, supporting long-term growth.
The outlook is positive with a consensus price target of $142.33 implying 16% upside, though high valuation multiples and rising debt levels pose risks. Analyst sentiment is mixed with 35% buy ratings, but institutional interest remains steady. Key catalysts include Q2 2026 earnings on July 24, 2026, and execution on new logistics contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Canadian National Railway Co.
Canadian National's railway spans Canada from coast to coast and extends through Chicago to the Gulf of Mexico. In 2019, CN delivered almost 6 million carloads over its 19,600 miles of track. CN generated roughly CAD 14 billion in total revenue by hauling intermodal containers (25% of consolidated revenue), petroleum and chemicals (21%), grain and fertilizers (16%), forest products (12%), metals and mining (11%), automotive shipments (6%), and coal (4%). Other items constitute the remaining revenue.
Read more on CNI →
